Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Gladstone Institutional Advisory LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% in the fourth ...

Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

The general mood among these heavyweight investors is divided, with 33% leaning bullish and 66% bearish. Among these notable options, 6 are puts, totaling $210,150, and 3 are calls, amounting to ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

Amgen (NASDAQ:AMGN – Get Free Report) had its target price increased by Piper Sandler from $310.00 to $329.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently ...

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

We recently published a list of Jim Cramer Discussed 10 Stocks Leading the Dow Higher in 2025. In this article, we are going ...

AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences ...

Many of them are still growth drivers, including Repatha, to treat high cholesterol; postmenopausal osteoporosis treatment Evenity; and Tepezza, for thyroid eye disease. Amgen has several other ...